NeuroSense Therapeutics (NRSN) Total Liabilities (2020 - 2025)
NeuroSense Therapeutics (NRSN) posted Total Liabilities of $2.6 million for Q4 2025, up 17.48% sequentially from $2.2 million in Q2 2025, and up 29.92% YoY from $2.0 million in Q4 2024.
NeuroSense Therapeutics (NRSN) Total Liabilities (2020 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Total Liabilities for 6 years, with the latest figure at $2.6 million in Q4 2025.
- Quarterly Total Liabilities rose 29.92% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (up 29.92% YoY) and the FY2025 annual result came in at $2.6 million, up 29.92% from the prior year.
- Total Liabilities grew to $2.6 million in Q4 2025 per NRSN's latest filing, from $2.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $9.4 million in Q2 2023 and troughed at $1.4 million in Q3 2022.
- A 5-year average of $3.6 million and a median of $2.4 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2024: Total Liabilities surged 1920.83% in 2021, then sank 62.35% in 2024.
- Over 5 years, Total Liabilities stood at $2.4 million in 2021, then retreated by 22.76% to $1.9 million in 2022, then surged by 163.96% to $4.9 million in 2023, then plunged by 59.71% to $2.0 million in 2024, then increased by 29.92% to $2.6 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.6 million, $2.2 million, and $2.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 2.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.59 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Mar 31, 2024 | 8.44 Mn |
| Dec 31, 2023 | 4.94 Mn |
| Sep 30, 2023 | 5.58 Mn |
| Jun 30, 2023 | 9.41 Mn |
| Mar 31, 2023 | 2.45 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.62 Mn |
| Mar 31, 2022 | 2.25 Mn |
| Dec 31, 2021 | 2.43 Mn |
| Dec 31, 2020 | 120,000.00 |